Refunds for Mallinckrodt’s top-selling drug is noticeably absent from recent posting.

Two High Profile Opioid Makers Among Companies Announcing Refunds to 340B Providers But Refunds for Mallinckrodt’s Top-Selling Drug Remain Elusive

For the fourth time since 2020, Purdue Pharma has announced refunds to 340B covered entities for overcharges. Purdue, which pled guilty in November in federal court to fraud and kickback charges related to its role in fueling the national opioid-abuse epidemic, said it would be providing refunds or credits for the painkillers OxyContin, Butrans and Hysingla as well as for the insomnia drug Intermezzo. The drugs were either produced by Purdue or its subsidiary Avrio Health.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report